SPOTLIGHT: GSK prepares pipeline update

Analysts are keenly awaiting tomorrow's presentation by GlaxoSmithKline on its brightest pipeline hopes. GSK is betting that its experimental vaccines -- like Cervarix -- can rev up its bottom line. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.